Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by kindvalueon Nov 19, 2019 1:31pm
221 Views
Post# 30370214

phase 3 data and financing

phase 3 data and financing . An outright hedge fund long / short who borrowed shares from management and others and then go short the stock into a financing (Don owns over 4M shares).  Hedge funds are in a no lose position on a postion like this especially if they gain wt coverage.  Follow the smart money when it comes to small caps especially biotech.  Hedge funds scare me. Looks like an MMCAP deal. MMCAP was the largest financier in the cannabis space.  Now look how these cannabis deals are trading - at a fraction of the price - decimated.  
Don has been spinning for 14 years.  14 years ago Don said he was not going to run FDA trials as what they had would attract partnering money.  Guess what, that did not play out and now he has run a massive trial and missed the primary end point. Now spin and not much cash remaining.  
Reminds me of the HSM Helius.  Look at April when HSM missed their end point.  And despite the spin the stock continues to slide to new lows like the pattern RVX is stuck - its hanging onto spin. Facts determine the long term value and spin eventually fizzles.   Don is keeping it alive - received total compensation of $1.9 million dollars last year.    
Bullboard Posts